Ultragenyx Pharmaceutical (NASDAQ:RARE) & Kamada (NASDAQ:KMDA) Critical Comparison

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Ultragenyx Pharmaceutical and Kamada, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1	11	9	1	2.45
Kamada	0	0	4	0	3.00

Ultragenyx Pharmaceutical presently has a consensus price target of $29.79, suggesting a potential upside of 86.15%. Kamada has a consensus price target of $13.75, suggesting a potential upside of 70.98%. Given Ultragenyx Pharmaceutical’s higher possible upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Kamada.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Kamada”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673.00 million	2.42	-$575.00 million	($5.19)	-3.08
Kamada	$180.46 million	2.56	$20.20 million	$0.43	18.70

Kamada has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Kamada’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-71.78%	N/A	-39.70%
Kamada	12.67%	9.36%	6.53%

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Kamada has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Insider and Institutional Ownership

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Kamada beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.

About Kamada

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.